1-15 of 15
B. Douglas Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Project Confirm: Accelerated Drug Approvals for CML—Response

Kendra L. Sweet, Jorge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler, Cristina Ruiz, Charles A. Schiffer, Lori A. Ehrlich, Gulsum E. Pamuk, Joseph Wynne, Gautam U. Mehta, Olanrewaju O. Okusanya, R. Angelo de Claro, Marc R. Theoret, B. Douglas Smith, Kelly J. Norsworthy
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 237–238.
https://doi.org/10.1158/1078-0432.CCR-23-3234
Published: 05 January 2024
View article titled, Project Confirm: Accelerated Drug Approvals for CML—Response
Open the PDF for Project Confirm: Accelerated Drug Approvals for CML—Response in another window
Journal Articles

Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia

Kendra L. Sweet, Jorge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler, Cristina Ruiz, Charles A. Schiffer, Lori A. Ehrlich, Gulsum E. Pamuk, Joseph Wynne, Gautam U. Mehta, R. Angelo de Claro, Marc R. Theoret, B. Douglas Smith, Kelly J. Norsworthy
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2179–2183.
https://doi.org/10.1158/1078-0432.CCR-22-2628
Published: 13 June 2023
View article titled, Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
Open the PDF for Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia in another window
Journal Articles

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Daniel A. Pollyea, Courtney D. DiNardo, Martha L. Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A. Rizzieri, B. Douglas Smith, Atsushi Shinagawa, Roberto M. Lemoli, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2753–2761.
https://doi.org/10.1158/1078-0432.CCR-21-3467
Published: 01 July 2022
View article titled, Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <em>IDH1/2</em> Mutations
Open the PDF for Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <em>IDH1/2</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia

Joshua F. Zeidner, Daniel J. Lee, Mark Frattini, Gil D. Fine, Judy Costas, Kathryn Kolibaba, Stephen P. Anthony, David Bearss, B. Douglas Smith
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (1): 60–69.
https://doi.org/10.1158/1078-0432.CCR-20-2649
Published: 04 January 2021
View article titled, Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia
Open the PDF for Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea M.H. Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David Rizzieri, Mark G. Frattini, Yair M. Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3519–3527.
https://doi.org/10.1158/1078-0432.CCR-17-3763
Published: 31 July 2018
View article titled, A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Open the PDF for A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary Rosner, Alice Chen, Scott H. Kaufmann, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 899–907.
https://doi.org/10.1158/1078-0432.CCR-16-1274
Published: 14 February 2017
View article titled, A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Open the PDF for A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Ivana Gojo, Jan H. Beumer, Keith W. Pratz, Michael A. McDevitt, Maria R. Baer, Amanda L. Blackford, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Mark J. Levis, Amy E. Dezern, Douglas E. Gladstone, Jiuping Jay Ji, Lihua Wang, Robert J. Kinders, Marie Pouquet, Ismail Ali-Walbi, Michelle A. Rudek, Weijie Poh, James G. Herman, Larry M. Karnitz, Scott H. Kaufmann, Alice Chen, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (3): 697–706.
https://doi.org/10.1158/1078-0432.CCR-16-0984
Published: 31 January 2017
View article titled, A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Open the PDF for A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms

Keith W. Pratz, Brian D. Koh, Anand G. Patel, Karen S. Flatten, Weijie Poh, James G. Herman, Robert Dilley, Maria I. Harrell, B. Douglas Smith, Judith E. Karp, Elizabeth M. Swisher, Michael A. McDevitt, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (15): 3894–3902.
https://doi.org/10.1158/1078-0432.CCR-15-2351
Published: 31 July 2016
View article titled, Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Open the PDF for Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

Judith E. Karp, Brian M. Thomas, Jacqueline M. Greer, Christopher Sorge, Steven D. Gore, Keith W. Pratz, B. Douglas Smith, Karen S. Flatten, Kevin Peterson, Paula Schneider, Karen Mackey, Tomoko Freshwater, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Douglas E. Gladstone, Margaret M. Showel, Sabine Loechner, David A. Parry, Jo Ann Horowitz, Randi Isaacs, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (24): 6723–6731.
https://doi.org/10.1158/1078-0432.CCR-12-2442
Published: 16 December 2012
View article titled, Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Open the PDF for Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias in another window
Journal Articles

Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

Erin L. Schenk, Brian D. Koh, Karen S. Flatten, Kevin L. Peterson, David Parry, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Larry M. Karnitz, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5364–5373.
https://doi.org/10.1158/1078-0432.CCR-12-0961
Published: 30 September 2012
View article titled, Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <em>In Vitro</em>
Open the PDF for Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <em>In Vitro</em> in another window
Includes: Supplementary data
Journal Articles

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

B. Douglas Smith, Yvette L. Kasamon, Jeanne Kowalski, Christopher Gocke, Kathleen Murphy, Carole B. Miller, Elizabeth Garrett-Mayer, Hua-Ling Tsai, Lu Qin, Christina Chia, Barbara Biedrzycki, Thomas C. Harding, Guang Haun Tu, Richard Jones, Kristen Hege, Hyam I. Levitsky
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 338–347.
https://doi.org/10.1158/1078-0432.CCR-09-2046
Published: 04 January 2010
View article titled, K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
Open the PDF for K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

Judith E. Karp, B. Douglas Smith, Ivana Gojo, Jeffrey E. Lancet, Jacqueline Greer, Maureen Klein, Larry Morris, Mark J. Levis, Steven D. Gore, John J. Wright, Elizabeth Garrett-Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 3077–3082.
https://doi.org/10.1158/1078-0432.CCR-07-4743
Published: 15 May 2008
View article titled, Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features
Open the PDF for Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features in another window
Journal Articles

Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia

Judith E. Karp, B. Douglas Smith, Mark J. Levis, Steven D. Gore, Jacqueline Greer, Catherine Hattenburg, Janet Briel, Richard J. Jones, John J. Wright, A. Dimitri Colevas
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4467–4473.
https://doi.org/10.1158/1078-0432.CCR-07-0381
Published: 01 August 2007
View article titled, Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia
Open the PDF for Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia in another window
Journal Articles

Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias

Judith E. Karp, Antonino Passaniti, Ivana Gojo, Scott Kaufmann, Keith Bible, Tushar S. Garimella, Jacqueline Greer, Janet Briel, B. Douglas Smith, Steven D. Gore, Michael L. Tidwell, Douglas D. Ross, John J. Wright, A. Dimitrios Colevas, Kenneth S. Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8403–8412.
https://doi.org/10.1158/1078-0432.CCR-05-1201
Published: 01 December 2005
View article titled, Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-<sc>d</sc>-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Open the PDF for Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-<sc>d</sc>-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias in another window
Journal Articles

E-Cadherin Expression Is Silenced by 5′ CpG Island Methylation in Acute Leukemia

Paul G. Corn, B. Douglas Smith, Emily S. Ruckdeschel, Donna Douglas, Stephen B. Baylin, James G. Herman
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (11): 4243–4248.
Published: 01 November 2000
View article titled, E-Cadherin Expression Is Silenced by 5′ CpG Island Methylation in Acute Leukemia
Open the PDF for E-Cadherin Expression Is Silenced by 5′ CpG Island Methylation in Acute Leukemia in another window